3rd ESTRO Forum 2015 S299 olaparib as radiosensitizer to efficacy of olaparib as single agent in cell systems with different genetic backgrounds. Materials and Methods: Mouse mammary tumor cell line with BRCA2 deficiency, its isogenic control cell line with restored BRCA2 function and a panel of human head and neck squamous cell carcinoma (HNSCC) cell lines were treated with different doses of olaparib and radiation. Survival was quantified using proliferation and clonogenic assays. To assess the effect of olaparib and radiation on PARP activity, we measured PAR levels using an ELISA-based immunoassay. Results: As reported previously, olaparib alone has efficacy at significantly lower concentrations in BRCA2-deficient cells than in BRCA2-proficient cells. Efficacy of olaparib alone differed among the human HNSCC cells. Olaparib radiosensitized all tested cell lines, however, to a different extent and at different dose ranges. Importantly, in all but one HNSCC cell line that is hypersensitive to olaparib alone, effective radiosensitization always established at tenfold lower concentrations than single agent activity. Radiation increased PAR levels in both BRCA2-deficient and BRCA2-proficient cells. Olaparib reduced PAR levels in a dose-dependent fashion and to a similar extent in BRCA2-deficient and BRCA2-proficient cells. Low doses of olaparib that result in effective radiosensitization without concomitant single agent activity fully abolished PAR induction by radiation, without fully abolishing baseline PAR levels. Conclusions: Our results show that olaparib acts as an effective radiosensitizer at significantly lower doses than those required for single agent activity. We conclude that olaparib-induced radiosensitization occurs by the prevention of PAR induction upon radiation, rather than by full PARP inhibition as proposed to be required for single agent activity. From these data we would predict that radiosensitization may be present at low olaparib dose levels in the clinic. This study emphasizes the importance to evaluate the concept of biological optimal dosing in novel radiation-targeted agent combinations.
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Conclusions:
A model to account GNP uptake and tissue radiosentitization was implemented and included in the simulation of breast cancer treatments. In addition to the improved treatment efficacy, the possibility of a short course of fractionation in combination with GNP was also quantified. Additionally, NW457 demonstrated potent anti-invasive activities by decreasing the inherent migration of LN229 cells as well as inhibiting irradiation-induced hypermigration. Conclusions: Taken together, our data on HSP90 inhibition as a clinically relevant, novel glioblastoma treatment concept suggests that the novel small-molecule inhibitor NW457 might improve the efficacy of radiotherapy via a dual mechanism involving (i) attenuation of radioresistance through induction of apoptosis and impairment of the DNA damage response and (ii) inhibition of both inherent and radiation-induced migration. 
